title: Are γ-secretase inhibitors detrimental for Alzheimer's disease patients?
abstract: The recent failure of semagacestat in two large Phase III studies questions the value of γ-secretase inhibitors in treating Alzheimer's disease. Understanding the reasons of this setback may be important for the future research on effective treatments for this devastating disease.
authors.affiliation: Memory Enhancement Center, Eatontown, New Jersey, USA.
authors.forename: Joel S
authors.initials: JS
authors.lastname: Ross
authors.forename: Bruno P
authors.initials: BP
authors.lastname: Imbimbo
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000201:enzymology; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans
chemical_list: D014150:Antipsychotic Agents; D004791:Enzyme Inhibitors; D053829:Amyloid Precursor Protein Secretases